Trump's 100% Drug Tariffs: The FDA Problem No One Is Talking About

Why Mid-Sized Pharma and Biotech Need to Move Now The headline was simple: On April 2, 2026, President Trump announced 100% tariffs on imported branded drugs and key drug ingredients. Most of the immediate reaction has focused on trade, geopolitics, and pricing. But for drug manufacturers—especially mid-sized branded pharma and specialty biotech—the more urgent risk is not at U.S. Customs. It is at FDA.... By: Maynard Nexsen